Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice‐weekly ixazomib plus Rd in NDM...

Full description

Saved in:
Bibliographic Details
Published in:Br J Haematol
Main Authors: Richardson, Paul G., Hofmeister, Craig C., Rosenbaum, Cara A., Htut, Myo, Vesole, David H., Berdeja, Jesus G., Liedtke, Michaela, Chari, Ajai, Smith, Stephen D., Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra Di, Estevam, Jose, Berg, Deborah, Baz, Rachid
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Haematological Malignancy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055619/
https://ncbi.nlm.nih.gov/pubmed/29938772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15394
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items